Results 91 to 100 of about 441,484 (310)

The polymeric stability of the Escherichia coli F4 (K88) fimbriae enhances its mucosal immunogenicity following oral immunization [PDF]

open access: yes, 2008
<p>Only a few vaccines are commercially available against intestinal infections since the induction of a protective intestinal immune response is difficult to achieve.
Cox, Eric   +9 more
core   +2 more sources

Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions

open access: yesOncoImmunology, 2021
CD8+ T cells are capable of recognizing mutation-derived neoantigens displayed by HLA class I molecules, thereby exhibiting the ability to distinguish between cancer and normal cells. However, accumulating evidence has shown that only a small fraction of
Tomoyo Shinkawa   +5 more
doaj   +1 more source

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. [PDF]

open access: yes, 2016
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a ...
Allali, Slimane   +4 more
core   +2 more sources

CD4+ Th immunogenicity of the Ascaris spp. secreted products [PDF]

open access: yes, 2020
Ascaris spp. is a major health problem of humans and animals alike, and understanding the immunogenicity of its antigens is required for developing urgently needed vaccines.
Bertazzon, Miriam   +6 more
core   +1 more source

QuilA-adjuvanted T. gondii lysate antigens trigger robust antibody and IFNγ+ T cell responses in pigs leading to reduction in parasite DNA in tissues upon challenge infection [PDF]

open access: yes, 2019
Toxoplasma gondii is an intracellular parasite of all mammals and birds, responsible for toxoplasmosis. In healthy individuals T. gondii infections mostly remain asymptomatic, however this parasite causes severe morbidity and mortality in ...
Cox, Eric   +6 more
core   +2 more sources

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID‐A study

open access: yesJournal of The American Geriatrics Society, 2021
The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID‐19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID‐
Sergio Salmerón Ríos   +14 more
semanticscholar   +1 more source

The immunogenicity and safety of the new, Indonesian DTwP-HB-Hib vaccine compared to the DTwP/HB vaccine given with the Hib vaccine

open access: yesPaediatrica Indonesiana, 2017
Background Haemophilus influenzae type b (Hib) causes infection with predominant manifestations of pneumonia, meningitis, and other invasive diseases, occurring primarily in children aged under 2 years, particularly in infants.
Novilia Sjafri Bachtiar   +4 more
doaj   +1 more source

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines [PDF]

open access: yes, 2018
Objective: The aim was to critically evaluate well-established regulatory agencies mAb biosimilar guidelines for development and marketing authorization about quality, efficacy and safety and compare to BRICS-TM regulations to identify challenges ...
Anvisa   +20 more
core   +4 more sources

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

open access: yesScience Advances, 2020
A rationally designed bi-adjuvant nanovaccine enhances neoantigen immunogenicity and enables combination immunotherapy. Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have ...
Qianqian Ni   +11 more
semanticscholar   +1 more source

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.

open access: yesJournal of the American Medical Association (JAMA), 2021
Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals Standard dosing intervals for BNT162b2 and mRNA-1273 SARSCoV-2 vaccines are 21 and 28 days, respectively.1 Data suggest improved effectiveness of ChAdOx1 adenoviral2 and other ...
B. Grunau   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy